Syntara shows encouraging first signals it can impact the path to Parkinson's
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...
Market Cap $72.85M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.10pm 06/07/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 5.0¢ | Day High | 5.0¢ | Day Low | 4.7¢ | |||
| Daily Volume | 1247287 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 4.7¢ | 37222 | 0 | 4.8¢ | 157091 | |
Directors & Senior Management
| Mr. Giuseppe Paolo Joseph Graziano | Non-Executive Director |
| Mr. Graham Leslie Ascough | Non-Executive Director |
| Mr. Hansjoerg Plaggemars | Non-Executive Director |
| Ms. Leah Moore | Chief Geologist |
| Mr. Robert Andrew Johnston | Non-Executive Chairman |
| Mr. Stephen Jones | CFO & Company Secretary |
| Mr. William John Ingram | MD, CEO & Director |
Data source: ADVFN
